Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard M Stone

Showing results (61-70 of 420) with videos related to

Pageof 42
Sort By:
The Journal of Rheumatology|July 3, 2017
Calcium Pyrophosphate Crystal Inflammatory Arthritis (Pseudogout) with Myelodysplastic Syndrome: A New Paraneoplastic Syndrome?Sara K Tedeschi, Richard M Stone, Simon M Helfgott
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Novel Therapeutics in Acute Myeloid LeukemiaCourtney D DiNardo, Richard M Stone, Bruno C Medeiros
Blood Advances|February 13, 2023
Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemiaRichard M Stone, Jessica K Altman, Mikkael A Sekeres
American Journal of Hematology|February 4, 2025
Biology and Management of Acute Myeloid Leukemia With Mutated NPM1Evan C Chen, Shai Shimony, Marlise R Luskin, et al.
Blood|September 11, 2004
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignanciesMartha Wadleigh, Daniel J DeAngelo, James D Griffin, et al.
Blood Cancer Journal|November 4, 2025
Correspondence on: Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched studyLuis E Aguirre, Richard M Stone, Daniel J DeAngelo, et al.
Blood Advances|March 1, 2018
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosisRichard M Stone, Paul W Manley, Richard A Larson, et al.
Leukemia & Lymphoma|September 30, 2021
Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?Jan Philipp Bewersdorf, Richard M Stone, Martin S Tallman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Fifty years of clinical research by the leukemia committee of the cancer and leukemia group BRichard A Larson, Richard M Stone, Robert J Mayer, et al.
The Lancet. Haematology|August 31, 2023
All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial resultsAmar H Kelkar, Shai Shimony, Edward R Scheffer Cliff, et al.
Pageof 42

Showing results (61-70 of 420) with videos related to

Sort By:
Pageof 42
The Journal of Rheumatology|July 3, 2017
Calcium Pyrophosphate Crystal Inflammatory Arthritis (Pseudogout) with Myelodysplastic Syndrome: A New Paraneoplastic Syndrome?Sara K Tedeschi, Richard M Stone, Simon M Helfgott
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Novel Therapeutics in Acute Myeloid LeukemiaCourtney D DiNardo, Richard M Stone, Bruno C Medeiros
Blood Advances|February 13, 2023
Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemiaRichard M Stone, Jessica K Altman, Mikkael A Sekeres
American Journal of Hematology|February 4, 2025
Biology and Management of Acute Myeloid Leukemia With Mutated NPM1Evan C Chen, Shai Shimony, Marlise R Luskin, et al.
Blood|September 11, 2004
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignanciesMartha Wadleigh, Daniel J DeAngelo, James D Griffin, et al.
Blood Cancer Journal|November 4, 2025
Correspondence on: Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched studyLuis E Aguirre, Richard M Stone, Daniel J DeAngelo, et al.
Blood Advances|March 1, 2018
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosisRichard M Stone, Paul W Manley, Richard A Larson, et al.
Leukemia & Lymphoma|September 30, 2021
Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?Jan Philipp Bewersdorf, Richard M Stone, Martin S Tallman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Fifty years of clinical research by the leukemia committee of the cancer and leukemia group BRichard A Larson, Richard M Stone, Robert J Mayer, et al.
The Lancet. Haematology|August 31, 2023
All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial resultsAmar H Kelkar, Shai Shimony, Edward R Scheffer Cliff, et al.
Pageof 42